CSI Market
Sign In | Register

Melinta Therapeutics (CEMP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CEMP Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Melinta Therapeutics's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2019)
9 Months 		(Jun 30 2019) (Mar 31 2019) (Dec 31 2018) (Sep 30 2018)
Operating Activities
Income-276.09
Depreciation & amortization12.68
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges176.73
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase2.14
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.52
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt3.04
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest-
Issuance Of Common Shares For License Agreement-
Adjustment To Liability For Potential Royalties-
Change In Fair Value Of Tranche Assets And Liabilities-
Nonoperating Income Expense-
Increase Decrease In Contract With Customer Liability-
Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss-10.96
Noncash Interest And Debt Amortization Expense11.62
Increase Decrease In Advance Payments For Inventory-0.91
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables3.55
Increase (Decrease) in Accounts Payable-7.77
Accrued Expense-7.18
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.57
Other Working Capital6.39
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.91
Discontinued operations0.00
Net Cash flow from Operating Activities-89.82
Investing Activities
Capital Expenditures-1.22
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.22
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-2.18
Long-term debt - borrowings75.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.06
Proceeds From Borrowing On Convertible Promissory Notes-
Payment Of Offering Costs-
Proceeds From Exercise Of Stock Option And Warrants-
Proceeds From Stock Options And Warrants Exercised-
Proceeds From Issuance Of Royalty Agreement-
Prepaid Notes Payable Disbursement Option-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities72.75
Effect of exchange rate on cash flow-18.29
Discontinued operations0.00
Free Cash Flow-91.04
Total Cash Flow-18.29
4 historic quarters locked

Sign in to unlock the full Melinta Therapeutics cash flow history.

Sign In Create Free Account

About CEMP Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.